...

Module

Toward Timely Treatment: Risks of and Strategies to Address Delayed Antiretroviral Therapy

Source: Toward Timely Treatment: Risks of and Strategies to Address Delayed Antiretroviral Therapy

Toward Timely Treatment: Risks of and Strategies to Address Delayed Antiretroviral Therapy


Faculty:

Keith Henry, MD
  • Keith Henry, MD

CREDIT INFORMATION

Release Date: 01/22/09

Expiration Date: 01/21/10


Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing contact hours

Status: Please log in to view status

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Specify current guidelines on routine opt-out HIV testing
  • Explain current guidelines on initiation of antiretroviral therapy
  • Discuss the clinical risks associated with initiation of antiretroviral therapy later than currently recommended
  • Debate the potential advantages and disadvantages of initiating antiretroviral therapy in all HIV-infected patients

Topics covered include:

  • Introduction
  • Updated Guidelines on When to Start Antiretroviral Therapy
  • The Goals of Antiretroviral Therapy
  • The Potential Benefits Associated With Initiating Antiretroviral Therapy in Patients With a CD4+ Cell Count > 350 cells/mm3
  • The Potential Risks Associated With Initiating Antiretroviral Therapy in Patients With a CD4+ Cell Count > 350 cells/mm3
  • Real-World Data on Timing of HIV Diagnosis and HAART Initiation
  • Recommendations for Expanded Use of HIV Testing
  • Barriers to Adoption of Routine HIV Testing Practices
  • Practical Suggestions to Promote Earlier Testing and Treatment
  • The Role of Treatment Guidelines in Shaping Policy and Practice
  • Conclusions

Abstract
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.